Patents Assigned to Cytognomix Inc.
  • Patent number: 11501545
    Abstract: Automation of microscopic pathological diagnosis relies on digital image quality, which, in turn, affects the rates of false positive and negative cellular objects designated as abnormalities. Cytogenetic biodosimetry is a genotoxic assay that detects dicentric chromosomes (DCs) arising from exposure to ionizing radiation. The frequency of DCs is related to radiation dose received, so the inferred radiation dose depends on the accuracy of DC detection. To improve this accuracy, image segmentation methods are used to rank high quality cytogenetic images and eliminate suboptimal metaphase cell data in a sample based on novel quality measures. When sufficient numbers of high quality images are found, the microscope system is directed to terminate metaphase image collection for a sample. The International Atomic Energy Agency recommends at least 500 images be used to estimate radiation dose, however often many more images are collected in order to select the metaphase cells with good morphology for analysis.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: November 15, 2022
    Assignee: CytoGnomix Inc.
    Inventors: Peter Keith Rogan, Yanxin Li, Jin Liu
  • Patent number: 10929641
    Abstract: An automated microscope system is described that detects dicentric chromosomes (DCs) in metaphase cells arising from exposure to ionizing radiation. The radiation dose depends on the accuracy of DC detection. Accuracy is increased using image segmentation methods are used to rank high quality cytogenetic images and eliminate suboptimal metaphase cell data in a sample based on novel quality measures. When a sufficient number of high quality images are detected, the microscope system is directed to terminate metaphase image collection for a sample. The microscope system integrates image selection procedures that control an automated digitally controlled microscope with the analysis of acquired metaphase cell images to accurately determine radiation dose. Early termination of image acquisition reduces sample processing time without compromising accuracy. This approach constitutes a reliable and scalable solution that will be essential for analysis of large numbers of potentially exposed individuals.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: February 23, 2021
    Assignee: CytoGnomix Inc.
    Inventors: Peter Keith Rogan, Yanxin Li, Jin Liu
  • Patent number: 9624549
    Abstract: A method for determining genes in breast cancer that are stable in copy number, expression and sequence in tumors from nearly all patients. Certain stable genes are targets of standard chemotherapy. The effectiveness of therapies that act upon these targets depends on maintaining the stability and integrity of these genes in tumors. Mutations in these targets result in poor response to therapies that target these gene products. In the instant invention, ordinarily stable gene targets are characterized as either normal or mutant for the purpose of determining whether to include or exclude particular drugs as potential treatments.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: April 18, 2017
    Assignee: Cytognomix Inc.
    Inventors: Peter Keith Rogan, Joan Helen Knoll
  • Publication number: 20150254397
    Abstract: A method is described for the automatic validation of DNA sequencing variants that alter mRNA splicing from nucleic acids isolated from a patient or tissue sample. Evidence the a predicted splicing mutation is demonstrated by performing statistically valid comparisons between sequence read counts of abnormal RNA species in mutant versus non-mutant tissues. The method leverages large numbers of control samples to corroborate the consequences of predicted splicing variants in complete genomes and exomes for individuals carrying such mutations. Because the method examines all transcript evidence in a genome, it is not necessary a priori to know which gene or genes carry a splicing mutation.
    Type: Application
    Filed: January 10, 2015
    Publication date: September 10, 2015
    Applicant: Cytognomix Inc
    Inventors: PETER KEITH ROGAN, STEPHANIE NICOLE DORMAN, COBY VINER, ELISEOS JOHN MUCAKI
  • Patent number: 8605981
    Abstract: A method for determining radiation exposure from chromosome abnormalities present in a specimen by determining the location or locations of the centromere of each chromosome in a cell in an image of a metaphase cell by segmentation of an accurately drawn chromosome centerline followed by selection of a longitudinal cross-section with the minimum width or intensity or width and intensity; counting the number of centromeres in each chromosome in each cell; computing the frequency of dicentric chromosomes in a population of cells; and determining the radiation dose by comparing the computed frequency of dicentric chromosomes with a previously determined dose-response curve from a calibrated source.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: December 10, 2013
    Assignee: Cytognomix Inc.
    Inventors: Peter Keith Rogan, Joan Helen Knoll, Jagath Samarabandu, Akila Subasinghe